Non Small Cell Lung Cancer

Phase II study of 1L pembrolizumab in pts ≥ age 70 with PDL1+ NSCLC by @NadalErnest and @gecp_org now @LungCaJournal. 1Y OS rate 62% with mOS 19.2m. Confirms expectations, helpful to have prospective data. Age should not deter proper therapy. https://t.co/SqLywYzNK1 (@StephenVLiu)

7/7 #TumorBoardTuesday Thurs Case🎀 🙏Careful discussion & individualized care, IO can be considered in neoadj setting for pts w autoimmune dz 🤔Better biomarkers 🎯 IO in future? 📅08.08: @MMarmarelis @norataranto explore tx after progression on Osimertinib in #EGFR m #NSCLC! (@JohnEbbenMDPhD)

Analysis of CROWN data (1L lorlatinib vs crizotinib) in #ALK NSCLC by EML4-ALK fusion variant and TP53 status @JTOonline. Given the clear biologic differences between variants (v3 vs others), I think it's time to stratify by variant and tailor strategies. https://t.co/iqJzIc5KEe (@StephenVLiu)

WATCH: Expert oncologists reflect on the state of molecular testing in NSCLC and how it informs the management of patients with uncommon EGFR mutations. @benlevylungdoc @hopkinskimmel @UMiamiHealth #lungcancer https://t.co/vp5pIxGdHx (@OncLive)

In #clinicaltrial EA5161, investigators at are testing a new treatment approach for patients with #NSCLC w/ EGFR ex20-ins mutations. For more: https://t.co/pwy12PyvBr cc: @ZPiotrowskaMD, @LeciaSequist (@eaonc)

#Clinicaltrial EA5162, led by @ZPiotrowskaMD and @LeciaSequist of @MGHCancerCenter, will evaluate how well osimertinib works in treating pts w/ advanced #NSCLC w/ EGFR ex20-ins mutations. Learn more here: https://t.co/pwy12PyvBr #lcsm (@eaonc)

Choose your player! Drs. @SusanScottMD and @Joshua_Reuss will face off at #DCLung23 on whether STK11/KEAP1 mutations should influence 1L NSCLC treatment. Visit us in downtown DC on Saturday, October 7, 2023 to vote! Full agenda registration at: https://t.co/rJa81GX23a (@StephenVLiu)

Delighted to share our latest paper on the mechanistic modeling of disease progression in EGFR-mutant lung adenocarcinoma: https://t.co/dsB0zfo9rc A special thanks to @MDuruisseaux & to all co-authors from @novadiscovery , @JanssenFRA. (@Claudio_MonT_s)

.@LudaBazhenovaMD, of @UCSDHealth, covered treatment and resistance with KRAS G12C inhibitors in NSCLC and highlighted MRTX1133 and RAS(ON), both KRAS G12D inhibitors. Still early stages but potential activity with RAS(ON) inhibitors in KRAS G12C-resistant disease #ILCC #lcsm (@OncLive)

ICYMI: The TIGIT inhibitor domvanalimab & the A2R antagonist etrumadenant enhances the clinical activity of the PD-1 inhibitor zimberelimab when administered as triplet therapy in pts w/ PD-L1–high, metastatic NSCLC. @MLJohnsonMD2 @SarahCannonDocs #lcsm https://t.co/z5dxHeQf1S (@OncLive)

Dr. @DDoroshow discusses RET fusions in NSCLC at #ILCC23 @gotoPER @MountSinaiNYC (@NarjustFlorezMD)

A multiD intervention (radiology, pathology, pharmacy, & oncology) ⬇️⬇️ time to start osimertinib for pts with #EGFR-mutant #NSCLC (5 vs 23 days) by directly analyzing frozen tissue & engaging pharmacy early: https://t.co/FHkNGChqVK #LungCancer #lcsm @IbiayiMD (@JCOOP_ASCO)

#Clinicaltrial EA5162, led by @ZPiotrowskaMD and @LeciaSequist of @MGHCancerCenter, will evaluate how well osimertinib works in treating pts w/ advanced #NSCLC w/ EGFR ex20-ins mutations. Learn more here: https://t.co/pwy12PyvBr #lcsm (@eaonc)

Impact of KRAS G12D and concurrent mutations on NSCLC outcomes. Our cohort shows 15.6% mKRAS (32, 32, 14% for G12C, G12D and G12V), G12D is associated with female and a lower smoking rate (pack/year). @incanMX @AndresFCardonaZ @Ecaballep https://t.co/YVgxHYVNAZ (@ogarrieta)

Paper published 🤩📄 Impact of KRAS G12D and concurrent mutations on NSCLC outcomes. Go and CHECK IT OUT! 🧬 Read 👉🏻 https://t.co/tKRM2KgL0c Team effort 🤩🫁 👨🏻‍⚕️@Ecaballep 👩🏽‍⚕️@YanHernandezP 👩🏻‍⚕️@maritza_rramos 👨🏻‍⚕️@AndresFCardonaZ 👨🏻‍⚕️ @ogarrieta #KRAS #NSCLC #outcome #UFOT #INCan (@UToracica)

Yes. This is not even that. This is lorlatinib for ped brain cancer prior to resection. And mutations not given. Lorlatinib has more data for nsclc w alk and brain Mets. (@VPrasadMDMPH)

Is anyone studying SBRT + IO? Encouraged by the recent success of SBRT + atezo in early stage NSCLC- but not sure if the same biological rationale is present here (maybe in later line or high TMB NETs) @RachelRiechelm2 (@JohnEbbenMDPhD)

This is lorlatinib for pediatric brain cancer (at least that is my impression) neo adjuvant. We don't know the mutational profile of the child. I doubt any country in Europe would cover it. It's not lorlatinib for nsclc with alk. (@VPrasadMDMPH)

Honored to write an invited editorial on "Zipalertinib in EGFR Exon 20–Mutant NSCLC" - out now in @JCO_ASCO @ASCO @StephenVLiu - we discuss the role of novel TKIs, and drug development in this rare, but increasingly crowded space! Congrats to the authors on this important… https://t.co/q2gu83PHLN (@CharuAggarwalMD)

Join experts @MLJohnsonMD2, @EnriquetaFelip, & Prof. Hayashi and improve your understanding of the next wave of novel #ADCs and how to incorporate them into clinical practice and trials for patients with #NSCLC. 9/12 at 13:00 SGT during #WCLC23: https://t.co/atVNPESBDE #MedEd (@PeerView)

New treatment in the horizon for patients with +BRAFV600E NSCLC waiting for a new treatment options. Phase II, Open-Label Study of #Encorafenib Plus #Binimetinib in Patients With #BRAFV600 Mutant Metastatic Non–Small-Cell Lung Cancer @RielyMD et al. N=98 💊ORR by IRR was 75%… https://t.co/nxhwhNjnff (@Latinamd)

Dr. @IbiayiMD will discuss #BRAF (both V600E and non) in NSCLC at #DCLung23 on Saturday, October 7, 2023. How should we sequence therapy in this important subtype? New options? Full agenda, faculty and registration at: https://t.co/rJa81GWudC (@StephenVLiu)

A unified effort is needed to improve #biomarker testing and applying testing results in #NSCLC clinical practice. Learn more from the @OncLive Biomarker Consortium at https://t.co/U4rPRSTLOU @esinghimd @StephenVLiu @LungCancerRx (@ADesaiMD)

Great point- might broaden to EVERYONE with adv NSCLC as now we can act on common alterations, eg KRas G12C too! CtDNA is a great but tricky tool-it lets u see the tip of the iceberg So if u see it- act on it but if not clearly informative, don’t let it steer your pt’s TITANIC! (@DrSteveMartin)

🚨Very high PD-L1 expression (>90%), high TMB, and increased CD8+PD1+ T cells density associate w/ prolonged benefit from CRT ➡️durvalumab in stage III #NSCLC. Out in @NatureComms our multi-center analysis led by🌟 @alessi_joao. #biomarkers can help⬆️outcomes. @OncoAlert #LCSM (@BiagioRicciutMD)

Impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC – @alessi_joao #MemorialSloanKetteringCancer #cancer #danafarber #durvalumab #pneumonitis #oncology #oncodaily https://t.co/CQD3cZyn5m (@oncodaily)

The @OncLive Biomarker Consortium is a new resource, which provides comprehensive information about the role of #biomarkers in diagnosis, treatment selection, & management of #NSCLC. Learn more at https://t.co/hxxM4kFi9I @StephenVLiu @esinghimd @ADesaiMD #lcsm #MedTwitter (@drshieldsmd)

Just wow! 4-year EFS 53% -> 77%, HR 0.38 [0.19-0.75] Another key gain for non-operative management in early stage NSCLC! (@5_utr)

Much needed study in the space of SBRT and IO for early stage NSCLC. Congratulations @JoeChangMD and MD Anderson team . (@NitikaPaudel)

I disagree with the FLAURA-2 analogy. The difference here is that targeted therapies for #EGFR exon 20 #NSCLC are no where near as good as sensitizing EGFR alterations. We should be comparing this data to Ph2 Chrysalis, where all participants got chemo first. (@TejasPatilMD)

Congrats!!! It is great to have another positive IO+RT study in #NSCLC #LCSM #radonc (@SouMyajiT_RO)

Findings from pivotal trials in NSCLC presented at the 2023 ASCO Annual Meeting displayed the potential benefit for perioperative treatment with EGFR TKIs or ICIs in select patient populations. @DrJNaidoo @CancerCentreIre @JCO_ASCO #ASCO2023 #lcsm https://t.co/CcTWyAzrzi (@OncLive)

Very important signal, IO maintenance after RT confirms its value in es-NSCLC: Stereotactic ablative radiotherapy with or without immunotherapy for e... https://t.co/8pVdyZ7eox @DrewMoghanaki @DoctorJSpicer @finn_corinne @Mat_Guc @HendriksLizza (@AndrearicFili)

We are hiring. Barcelona @NadalErnest is looking for a postdoc to decipher genetic traits of lung cancer (NSCLC) and mesothelioma patients @crismunozp is looking for someone to investigate how to best target metabolic stress (Integrated Stress Response) in NSCLC Mail us? (@NadalErnest)

We are hiring. Barcelona Ernest Nadal @NadalErnest is looking for a postdoc to decipher genetic traits of lung cancer (NSCLC) and mesothelioma patients Cris MP is looking for someone to investigate how to best target metabolic stress (Integrated Stress Response) in NSCLC Mail us? (@apoptosislab)

For additive effect compared to either alone? In NSCLC KN799 and Pacific2 but OS not mature (@PatelOncology)

What is your area of interest for this year's #EGFRSummit? Deadline to Submit Abstracts: Aug 18 ➡️➡️ https://t.co/vNTrKAG9JO @egfrresisters & @CEC_onc @jillfeldman4 @ivybelkins @ZPiotrowskaMD #EGFR #NSCLC #LCSM (@EGFRSummit)

Disseminated small cell lung cancer is an extreme example. It's not as if second-line NSCLC has such a long time line that we can't get a timely answer to OS. We have erred way too much on side of surrogate endpoints giving us false signals. And those who say PFS alone should… https://t.co/NlkQ0HgocY (@JackWestMD)

- CML imatinib (& other rarer dz) - EGFR, ALK, ROS, & others in NSCLC - HER2 in breast, gastric Ca - BRAF/MEK in melanoma, thyroid & others - FLT3, IDH in AML (tho trial designs variable) - PSMA in Lu-PSMA @Dr_R_Kurzrock (@Eddie_Cliff)

Hear different viewpoints on PD-L1 Levels and get the latest updates in the field on #Immunotherapy, #TargetedTherapies and #NSCLC. View agenda: https://t.co/cit9JHAWnQ @CoreyLangerMD @ChaftJamie @ChristianRolfo @DrSimone @LealTiciana @FordePatrick @ReckampK @LudaBazhenovaMD (@GreatDebatesCME)

🔥🚨@OncoAlert Just out @JTOonline by our team @MayoCancerCare: #CaseReport on a sequential #SmallCell transformation & #ALK I1171T mutation as resistance mechanisms in a pt with #ALK-EML4 #NSCLC treated with combination of #Temozolomide & #Lorlatinib 👇🏼 https://t.co/GkixRkDWr5 (@RManochakian)

A lot to unpack but it's all in there. I want to see more on NSCLC and VAC2. Let's break some news soon. (@josephnparsons)